CY-208,243

CY-208,243

CY-208,243 is a drug that acts as a dopamine D1 receptor partial agonist, and has antipsychotic properties. It was researched as a potential treatment for schizophrenia and Parkinson's disease, but was never marketed.

Pharmacology

CY-208,243 is a dopamine D1 receptor partial agonist. This means it binds to the D1 receptors in the brain and partially stimulates them, which can have various effects on the body. The D1 receptors are one of the five types of dopamine receptors in the brain, and they are involved in a variety of functions including motor control, cognition, and reward.

In preclinical studies, CY-208,243 showed antipsychotic-like activity, suggesting it could be useful in the treatment of conditions like schizophrenia. It also showed potential for the treatment of Parkinson's disease, a neurodegenerative disorder characterized by the death of dopamine-producing cells in the brain.

History

CY-208,243 was developed by the pharmaceutical company Ciba-Geigy, now part of Novartis. It was investigated as a potential treatment for schizophrenia and Parkinson's disease in the 1980s and 1990s, but it was never brought to market. The reasons for this are not publicly known, but could include a variety of factors such as lack of efficacy, undesirable side effects, or commercial considerations.

See also

• Dopamine receptor D1
• Dopamine agonist
• Antipsychotic
• Schizophrenia
• Parkinson's disease